ArticleDisease models & mechanisms
A murine model of myeloma that allows genetic manipulation of the host microenvironment.
Article in Disease models & mechanisms. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma.Nature communications · 2026Article
- Interferon gamma-mediated prevention of tumor progression in a mouse model of multiple myeloma.HemaSphere · 2024Article
- LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway.Journal of experimental & clinical cancer research : CR · 2024Article
- Endogenous CD28 drives CAR T cell responses in multiple myeloma.bioRxiv : the preprint server for biology · 2024Article
- Extramedullary multiple myeloma patient-derived orthotopic xenograft with a highly altered genome: combined molecular and therapeutic studies.Disease models & mechanisms · 2021Article
- Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.Cancer research · 2021Article
- Animal Models of Multiple Myeloma Bone Disease.Frontiers in genetics · 2021Review
- Bone-Seeking Matrix Metalloproteinase Inhibitors for the Treatment of Skeletal Malignancy.Pharmaceuticals (Basel, Switzerland) · 2020Article
- Osteotropic Radiolabeled Nanophotosensitizer for Imaging and Treating Multiple Myeloma.ACS nano · 2020Article
- Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment.Scientific reports · 2019Article
- Leflunomide regulates c-Myc expression in myeloma cells through PIM targeting.Blood advances · 2019Article
- Sprague DawleyMolecular cancer therapeutics · 2018Article
- Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myelomaJournal of bone oncology · 2018Review
- Review
- Impact of connexin 43 coupling on survival and migration of multiple myeloma cells.Archives of medical science : AMS · 2017Article
- Selective inhibition of matrix metalloproteinase-2 in the multiple myeloma-bone microenvironment.Oncotarget · 2017Article
- A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo.Molecular cancer · 2017Article
- Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance.Archives of medical science : AMS · 2017Article
- Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.The Journal of clinical investigation · 2016Article
- Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.Nature reviews. Rheumatology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Multiple myeloma, and the associated osteolytic bone disease, is highly dependent upon cellular interactions within the bone marrow microenvironment. A major limitation of existing myeloma models is the requirement for a specific host strain of mouse, preventing molecular examination of the bone marrow microenvironment. The aim of the current study was to develop a model of myeloma in which the host microenvironment could be modified genetically. The Radl 5T murine model of myeloma is well characterized and closely mimics human myeloma. In the current study, we demonstrate 5T myeloma establishment in recombination activating gene 2 (RAG-2)-deficient mice, which have improper B- and T-cell development. Importantly, these mice can be easily bred with genetically modified mice to generate double knockout mice, allowing manipulation of the host microenvironment at a molecular level. Inoculation of 5TGM1 myeloma cells into RAG-2(-/-) mice resulted in myeloma development, which was associated with tumor growth within bone and an osteolytic bone disease, as assessed by microcomputed tomography (microCT), histology and histomorphometry. Myeloma-bearing RAG-2(-/-) mice displayed many features that were similar to both human myeloma and the original Radl 5T model. To demonstrate the use of this model, we have examined the effect of host-derived matrix metalloproteinase 9 (MMP-9) in the development of myeloma in vivo. Inoculation of 5TGM1 myeloma cells into mice that are deficient in RAG-2 and MMP-9 resulted in a reduction in both tumor burden and osteolytic bone disease when compared with RAG-2-deficient wild-type myeloma-bearing mice. The establishment of myeloma in RAG-2(-/-) mice permits molecular examination of the host contribution to myeloma pathogenesis in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.